MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors..

迈阿密，2024年5月6日（环球通讯社）--SAB Biotherapeutics（纳斯达克：SABS）（“公司”或“SAB”）是一家临床阶段的生物制药公司，拥有一种新型免疫治疗平台，开发了一种人类抗胸腺细胞免疫球蛋白（hIgG），用于延缓1型糖尿病（T1D）的发作或进展，今天宣布Jay Skyler，MD，MACP，FRCP已被任命为公司董事会成员。。

“Dr. Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J. Reich, SAB’s chairman and Chief Executive Officer. “His deep expertise in type 1 diabetes research and leadership in the field will provide insights that will be invaluable to our SAB-142 program. Speaking on behalf of the Board, we are honored to add Dr.

SAB董事长兼首席执行官塞缪尔·赖希（SamuelJ.Reich）表示：“斯凯勒博士被任命为我们的董事会成员是SAB的一个重要里程碑。“他在1型糖尿病研究方面的深厚专业知识和在该领域的领导力将为我们的SAB-142计划提供宝贵的见解。

Skyler to the Board of Directors and look forward to his contributions as we continue to advance a disease-modifying therapy.”.

斯凯勒向董事会致辞，并期待着他在我们继续推进疾病缓解疗法的过程中做出贡献。”。

“I look forward to a future where we may delay the onset or progression of type 1 diabetes, and I’m optimistic about SAB’s potential role in that milestone with the novel approach of SAB-142,” noted Dr. Skyler of his appointment. “Disease modification is a nascent but critically important field, particularly in type 1 diabetes where prevention of immune destruction and preservation of beta cell mass or function are both considered ideal therapeutic goals.”.

斯凯勒博士在接受任命时表示：“我期待着未来我们可能会延缓1型糖尿病的发作或进展，我对SAB-142的新方法在这一里程碑中的潜在作用持乐观态度。”。“疾病修饰是一个新兴但至关重要的领域，特别是在1型糖尿病中，预防免疫破坏和保存β细胞质量或功能都被认为是理想的治疗目标。”。

Dr. Skyler’s career in diabetes spans more than five decades, and he is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, where he served as Director of that Division from 2000 to 2004.

斯凯勒博士在糖尿病方面的职业生涯跨越了50多年，目前是佛罗里达州迈阿密大学伦纳德·米勒医学院医学系内分泌糖尿病与代谢系的医学、儿科和心理学教授，2000年至2004年任该系主任。

From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial - Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to interdict type 1 diabetes..

从1993年到2015年，他担任美国国立卫生研究院（NIDDK）赞助的1型糖尿病预防试验（DPT-1）及其继任者1型糖尿病试验网（Type 1 Diabetes TrialNet）的主席，该试验网是一个全国（和全球）的网络，进行临床试验以阻断1型糖尿病。。

He is Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute, University of Miami, where he previously was Area Leader for Immunomodulation and Tolerance. He also is a Member of the University of Miami Interdisciplinary Stem Cell Institute.

他是迈阿密大学糖尿病研究所（Diabetes Research Institute，University of Miami）临床研究和学术项目的副主任，此前曾任该所免疫调节和耐受领域的领导者。他也是迈阿密大学跨学科干细胞研究所的成员。

A native of Philadelphia, Dr. Skyler is a graduate of Pennsylvania State University and Jefferson Medical College, and did his postgraduate training in Internal Medicine and in Endocrinology & Metabolism at Duke University Medical Center.

斯凯勒博士出生于费城，毕业于宾夕法尼亚州立大学和杰斐逊医学院，并在杜克大学医学中心接受内科和内分泌与代谢方面的研究生培训。

About SAB-142

关于SAB-142

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical trials T1D, demonstrating the ability to slow down disease progression in patients with new or recent onset of Stage 3 type 1 diabetes..

SAB-142是兔抗胸腺细胞球蛋白（ATG）的人类替代品。SAB-142的作用机制类似于兔ATG，已在多项临床试验T1D中进行了临床验证，证明其能够减缓新发或近期发作的3型糖尿病患者的疾病进展。。

Two clinical trials have shown that a single, low dose of rabbit ATG has demonstrated the ability to modulate the body’s immune response to help slow beta cell destruction and preserve the ability of these cells to generate insulin, which the body needs to regulate blood sugar and carry out all human activities..

两项临床试验表明，单次低剂量的兔ATG已经证明能够调节人体的免疫反应，以帮助减缓β细胞的破坏，并保持这些细胞产生胰岛素的能力，而胰岛素是人体调节血糖和进行所有人类活动所需的。。

SAB-142, like rabbit ATG, directly targets multiple immune cells involved in destroying pancreatic beta cells. By stopping immune cells from attacking beta cells, this treatment has potential to preserve insulin-producing beta cells. However, most humans treated with rabbit ATG develop serum sickness and anti-drug antibodies from exposure to the rabbit-derived antibody.

与兔ATG一样，SAB-142直接靶向参与破坏胰腺β细胞的多种免疫细胞。通过阻止免疫细胞攻击β细胞，这种治疗有可能保存产生胰岛素的β细胞。然而，大多数用兔ATG治疗的人由于暴露于兔源性抗体而产生血清病和抗药物抗体。

SAB-142 is a human antibody, intended to allow safe, consistent re-dosing for type 1 diabetes, a lifelong chronic disease, without the potential risk of inducing the major adverse immune reactions that can occur with administration of an animal ATG..

SAB-142是一种人类抗体，旨在为1型糖尿病（一种终身慢性疾病）提供安全，一致的重新给药，而不会产生诱发动物ATG可能发生的主要不良免疫反应的潜在风险。。

About SAB Biotherapeutics, Inc.

关于SAB Biotherapeutics，Inc。

SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression.

SAB Biotherapeutics（SAB）是一家临床阶段的生物制药公司，专注于开发人类，多靶点，高效免疫球蛋白（IgG），无需人类供体或恢复期血浆，以治疗和预防免疫和自身免疫性疾病。该公司的主要资产SAB-142以T1D为目标，采用一种改变疾病的治疗方法，旨在通过延迟发病和潜在地预防疾病进展来改变治疗模式。

Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.

SAB的DiversitAb™药物开发生产系统利用先进的基因工程和抗体科学开发了唯一具有人类人工染色体的转基因动物Transchromosomic（Tc）Bovine™，能够产生多种特异性靶向，高效的人类IgG，可以解决人类疾病中广泛的严重未满足需求，而无需恢复期血浆或人类供体。

For more information on SAB, visit: https://www.SAB.bio/ and follow SAB on Twitter and LinkedIn..

有关SAB的更多信息，请访问：https://www.SAB.bio/并在Twitter和LinkedIn上关注SAB。。

Forward-Looking Statements

前瞻性声明

Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

根据1995年《私人证券诉讼改革法案》的安全港规定，本报告中某些非历史事实的陈述是前瞻性陈述。前瞻性陈述通常伴随着“相信”、“可能”、“将会”、“未来”、“估计”、“继续”、“预期”、“打算”、“期望”、“应该”、“会”、“计划”、“预测”、“潜在”、“看起来”、“寻求”、“未来”、“展望”等词语，以及预测或指示未来事件或趋势或不属于历史事项陈述的类似表达。

These forward-looking statements include, but are not limited to, statements regarding future events, including, the impact members of SAB’s leadership team will have on the Company’s business and results of operations, and the development and efficacy of our T1D program and other discovery programs..

这些前瞻性声明包括但不限于关于未来事件的声明，包括SAB领导团队成员对公司业务和经营成果的影响，以及我们的T1D计划和其他发现计划的发展和有效性。。

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control.

这些声明基于SAB当前的预期，不是对实际表现的预测，不打算也不可被任何投资者作为事实或概率的担保、预测、最终声明或保证。这些声明只是当前的预测或预期，并受到已知和未知风险、不确定性和其他可能超出我们控制的因素的影响。

Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S.

实际事件和情况很难或不可能预测，这些风险和不确定性可能导致我们或我们行业的结果、业绩或成就与这些前瞻性陈述所预期的结果、业绩或成就存在重大差异。有关风险和不确定性的进一步说明，请参阅我们最近的10-K表年度报告中标题为“风险因素”的部分、随后的10-Q表季度报告（可能会不时修订或补充）以及其他提交给美国的文件或提交给美国的文件。

Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise..

证券交易委员会，可在https://www.sec.gov/.除非法律另有要求，否则南非国家统计局不打算或有义务更新或修订任何前瞻性声明，这些声明仅在其发布之日起发表，无论是由于新信息、未来事件或情况或其他原因。。

CONTACTS

联系人

Media Relations:

媒体关系：

khollon@sab.bio

khollon@sab.bio

Investor Relations:

投资者关系：

matt@milestone-advisorsllc.com

matt@milestone-advisorsllc.com